Method optimization for the quantification of the NAD metabolome in human whole blood, and evaluation of baseline inter and intra-subject variability.
Whole blood from healthy participants will be collected to optimize analytical method based on liquid chromatography tandem mass spectrometry (LC-MS/MS) for the analysis of the NAD metabolome in biological samples. Parameters such as collection volume and anti-coagulants will be investigated for optimal quantification. Moreover, inter- and intra-subject variability of NAD metabolite levels in whole blood will be evaluated. Plasma and urine will also collected for method development and variability measurements.
Study Type
OBSERVATIONAL
Enrollment
10
Test several sampling conditions
Clinical Innovation Lab.
Lausanne, Switzerland
Comparison of NAD metabolite concentrations in whole blood, collected with different tubes and anticoagulants.
NAD metabolites in whole blood will be quantified by liquid chromatography-tandem
Time frame: through study completion, an average of 1 year
Estimation of inter- and intra-subject variabilities of NAD metabolites in whole blood
Descriptive estimates of the inter and intra subjects variances will be calculated with the standard formulas.
Time frame: through study completion, an average of 1 year
Validation of the method for a set of NAD metabolites in plasma and urine (including determination of Limit Of Detection-LOD, Limit Of Quantification- LOQ).
NAD metabolites in urine and in blood will be quantified to enable to measure several validation parameters, such as intra and interday precision, LOD, LOQ, r2.
Time frame: through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.